The definition and meaning of treatment-resistant depression

Journal of Clinical Psychiatry

Volumn 62, Issue SUPPL. 16, 2001, Pages 10-17+35

  Sackeim, H A ^a  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; AMFEBUTAMONE; AMITRIPTYLINE; AMOXAPINE; ANTIDEPRESSANT AGENT; BUSPIRONE; CARBAMAZEPINE; CHLORPROMAZINE; CHLORPROTHIXENE; CITALOPRAM; CLOMIPRAMINE; CLONAZEPAM; CLONIDINE; CLOZAPINE; DESIPRAMINE; DEXAMPHETAMINE; DIPHENHYDRAMINE; DOXEPIN; FLUOXETINE; FLUVOXAMINE MALEATE; GABAPENTIN; HALOPERIDOL; LAMOTRIGINE; LEVOTHYROXINE SODIUM; LIOTHYRONINE SODIUM; LORAZEPAM; LOXAPINE SUCCINATE; MESORIDAZINE BESYLATE; METHYLPHENIDATE; MIRTAZAPINE; MOLINDONE; NEFAZODONE; ROMERON; UNINDEXED DRUG;

DEPRESSION; DOSE RESPONSE; DRUG EFFECT; HUMAN; MANIC DEPRESSIVE PSYCHOSIS; MEDICAL DECISION MAKING; MENTAL HEALTH CARE; OCCUPATIONAL HEALTH; PRIORITY JOURNAL; REMISSION; REVIEW; TREATMENT FAILURE; TREATMENT OUTCOME;

AFFECTIVE DISORDERS, PSYCHOTIC; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; CLINICAL TRIALS; DEPRESSIVE DISORDER; DRUG THERAPY, COMBINATION; ELECTROCONVULSIVE THERAPY; HUMANS; MEDICAL RECORDS; RECURRENCE; TERMINOLOGY; TREATMENT OUTCOME;

EID: 0034934926     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Management options for refractory depression
2. Declaration of treatment failures
3. Treatment-resistant depression
4. Moclobemide and fiuoxetine in the prevention of relapses following acute treatment of depression
5. Antidepressant efficacy and quality of life in depression: A double-blind study with moclobemide and fluoxetine
6. A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression
7. The National Depressive and Manic-Depressive Association consensus statement on the undertreatment of depression
8. Treatment-resistant mood disorders
9. Low levels and lack of predictors of somatotherapy and psychotherapy received by depressed patients
10. Treatment received by depressed patients
11. Course of treatment received by depressed patients
12. Medication resistance and clinical response to electroconvulsive therapy
13. Resistance to antidepressant medications and short-term clinical response to ECT
14. Plasma nortriptyline levels: Relationship to clinical effects
15. On the role of plasma level monitoring of tricyclic antidepressants in clinical practice
16. The impact of medication resistance and continuation pharmacotherapy on relapse following response to electroconvulsive therapy in major depression
17. Low use of neuroleptic drugs in the treatment of psychotic major depression
18. Antidepressant treatment is inadequate in patients with major depression who are at risk for suicidal behavior
19. Duration of antidepressant drug treatment: What is an adequate trial?
20. Can the effects of antidepressants be observed in the first two weeks of treatment?
21. The treatment of affective disorders in the elderly
22. Continuation drug therapy for major depressive episodes: How long should it be maintained?
23. A prospective, randomized, double-blind comparison of bilateral and right unilateral electroconvulsive therapy at different stimulus intensities
24. Treatment resistant depression: Methodological overview and operational criteria
25. The pharmacological treatment of delusional depression
26. Psychotic (delusional) depression: A meta-analysis of physical treatments
27. Neuroleptic dose and desipramine concentrations during combined treatment of unipolar delusional depression
28. The expert consensus guideline series: Medication treatment of bipolar disorder 2000
29. The efficacy of lamotrigine in rapid cycling and non-rapid cycling patients with bipolar disorder
30. Lamotrigine in the treatment of bipolar depression
31. Spectrum of activity of lamotrigine in treatment-refractory bipolar disorder
32. Antidepressant specificity in atypical depression
33. Relevance of DSM-III depressive subtype and chronicity of antidepressant efficacy in atypical depression: Differential response to phenelzine, imipramine, and placebo
34. Electroconvulsive therapy: Clinical and biological aspects
35. Depression duration but not age predicts hippocampal volume loss in medically healthy women with recurrent major depression